Michael Polansky’s AI‑trained living‑skin platform aims to fast‑track discovery of novel skincare actives, merging biotech with machine learning
Executive summary: Michael Polansky has spent years developing a startup that keeps living human skin tissue alive ex‑vivo for weeks and uses it to train an AI model to discover novel skincare actives. The platform could accelerate the identification of effective cosmetic ingredients, lower reliance on animal testing, and provide a proprietary AI‑biotech data asset that may be licensed or partnered with major beauty companies.
Who is involved: Michael Polansky (founder), his undisclosed startup team, and likely collaborators in tissue‑culture and AI; no external partners are named in the source.
Likely next: The startup may seek a seed or series A round by late 2026, publish initial validation studies in mid‑2027, and enter pilot agreements with cosmetics firms within the next 6‑12 months.
Michael Polansky has built a startup that maintains living human skin tissue outside the body for weeks and uses it as a training set for an AI model to identify new skincare compounds. The approach could shorten cosmetic R&D cycles, reduce animal testing, and create a defensible data‑driven moat for the company. While still early stage, the venture sits at the intersection of high‑growth AI and premium beauty markets, attracting potential interest from both biotech investors and large cosmetics firms.
Timeline
- — Michael Polansky is training an AI model on skin that’s still alive (TechCrunch)
Analysis — what this means
Likely next events
- Seed funding announcement expected Q4 2026
- First peer‑validated study on an AI‑identified compound projected for mid‑2027
- Potential FDA pre‑submission meeting for the living‑skin assay slated for early 2028
Sectors affected
- Skincare & cosmetics
- Biotechnology (tissue culture)
- AI-driven drug discovery
Regulatory implications
- FDA may require an IND‑style submission for using living human skin in cosmetic testing (21 CFR Part 812)
- EU Cosmetics Regulation could demand a full safety dossier for novel actives discovered via the platform
- Donor consent and data privacy rules akin to HIPAA apply to the sourcing and handling of human tissue
Historical parallels
- L’Oréal’s 3D printed skin models for toxicity testing (2020)
- Emulate’s organ‑on‑a‑chip liver platform (2018)
- Ginkgo Bioworks’ AI‑guided strain design for fragrance molecules (2022)